Novartis AG Share Price London S.E.

Equities

0QM7

CH0038459415

Pharmaceuticals

Market Closed - London S.E. 16:59:30 21/05/2018 BST 5-day change 1st Jan Change
76.86 CHF -1.00% Intraday chart for Novartis AG -0.77% -.--%

Financials

Sales 2024 * 48.92B 44.46B 3,852B Sales 2025 * 50.86B 46.21B 4,004B Capitalization 210B 191B 16,528B
Net income 2024 * 10.42B 9.47B 821B Net income 2025 * 11.92B 10.83B 938B EV / Sales 2024 * 4.54 x
Net Debt 2024 * 12.44B 11.3B 979B Net Debt 2025 * 11.34B 10.31B 893B EV / Sales 2025 * 4.35 x
P/E ratio 2024 *
20.1 x
P/E ratio 2025 *
17.2 x
Employees -
Yield 2024 *
3.51%
Yield 2025 *
3.64%
Free-Float 85.22%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 48 31/12/04
Director of Finance/CFO 59 31/12/02
Chief Tech/Sci/R&D Officer 62 15/05/22
Members of the board TitleAgeSince
Director/Board Member 62 31/12/12
Director/Board Member 65 27/02/20
Chairman 68 31/12/12
More insiders
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
102.9 USD
Average target price
107.9 USD
Spread / Average Target
+4.91%
Consensus